Multi-center and Multi-modal Deep Learning Study of Gastric Cancer

NCT ID: NCT05001321

Last Updated: 2021-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assist postoperative pathological diagnosis and classification of gastric cancer by machine learning; To improve the accuracy of pathological diagnosis of gastric cancer by machine learning; To predict the effectiveness of treatment for gastric cancer by deep learning; To construct a model to predict the survival of gastric cancer patients by multimodal deep learning.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stomach Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Training Group

Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.

The whole abdomen contrast-enhanced CT scan

Intervention Type RADIATION

All the participants were measured by the whole abdomen contrast-enhanced CT scan.

H&E stained sections and slides

Intervention Type OTHER

HE pathological examination was performed on all specimens of enrolled patients.

Internal Validation Group

Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.

The whole abdomen contrast-enhanced CT scan

Intervention Type RADIATION

All the participants were measured by the whole abdomen contrast-enhanced CT scan.

H&E stained sections and slides

Intervention Type OTHER

HE pathological examination was performed on all specimens of enrolled patients.

External Validation Group

Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.

The whole abdomen contrast-enhanced CT scan

Intervention Type RADIATION

All the participants were measured by the whole abdomen contrast-enhanced CT scan.

H&E stained sections and slides

Intervention Type OTHER

HE pathological examination was performed on all specimens of enrolled patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The whole abdomen contrast-enhanced CT scan

All the participants were measured by the whole abdomen contrast-enhanced CT scan.

Intervention Type RADIATION

H&E stained sections and slides

HE pathological examination was performed on all specimens of enrolled patients.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The diagnosis of gastric cancer was confirmed by pathology;
* Preoperative enhanced abdominal CT;
* Available detailed clinical and pathological data;
* Integrated follow-up data.

Exclusion Criteria

* The patients had severe underlying disease;
* Overall survival was less than 3 months;
* No detailed information could be collected.
Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Second Hospital of Shandong University

OTHER

Sponsor Role collaborator

Chaoyang Central Hospital

OTHER

Sponsor Role collaborator

The General Hospital of Fushun Mining Bureau

UNKNOWN

Sponsor Role collaborator

The fourth People's Hospital of Changzhou

UNKNOWN

Sponsor Role collaborator

First Hospital of Jinzhou Medical University

UNKNOWN

Sponsor Role collaborator

First Hospital of China Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kai Li

Deputy Director of surgical Oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kai Li, MD

Role: PRINCIPAL_INVESTIGATOR

First Hospital of China Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The fourth People's Hospital of Changzhou

Changzhou, Jiangsu, China

Site Status

Chaoyang Central Hospital

Chaoyang, Liaoning, China

Site Status

The General Hospital of Fushun Mining Bureau

Fushun, Liaoning, China

Site Status

First Hospital of Jinzhou Medical University

Jinzhou, Liaoning, China

Site Status

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Site Status

The Second Hospital of Shandong University

Ji'nan, Shandong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FirstHCMU_DL_oncology

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioinformation Therapy for Gastric Cancer
NCT03350477 COMPLETED PHASE2/PHASE3
Gut Microbiota and Metabonomics
NCT05205187 RECRUITING